

# ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults

## Position

Osteoporosis is a devastating disease that may lead to significant morbidity and mortality from resultant fractures.<sup>1-3</sup> The efficacy of medications as one method to prevent and treat osteoporosis and avert future fractures, particularly vertebral fractures, is well documented in large clinical trials. However, despite this evidence, many patients at risk for osteoporosis are not screened or treated.<sup>4-8</sup> Screening for osteoporosis is considered a quality-of-care indicator by the Centers for Medicare and Medicaid Services and the National Committee for Quality Assurance.<sup>9,10</sup> The American Society of Health-System Pharmacists (ASHP) believes that all women age 65 years or older, postmenopausal women younger than age 65 years who have an increased risk of developing osteoporosis, all adult women with a history of nontraumatic fracture, and men with a significant risk of fracture should be screened for osteoporosis and treated, if indicated.

ASHP believes that there is a gap between the evidence and practice of prevention and treatment of osteoporosis in adults. In addition, ASHP believes that prevention and treatment of osteoporosis can decrease the morbidity and mortality associated with this condition, consistent with the *Healthy People 2010* objectives of reducing the percentage of adults with osteoporosis and those hospitalized with vertebral fractures.<sup>11</sup> Calcium and vitamin D,<sup>12-17</sup> bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid),<sup>18-25</sup> calcitonin,<sup>26</sup> estrogen (with or without a progestin),<sup>27,28</sup> raloxifene,<sup>29</sup> and teriparatide<sup>30</sup> have all been shown to decrease the risk of osteoporotic fractures, though differences exist in each drug's ability to reduce fractures at all sites. Therefore, each drug's place in therapy varies.

ASHP encourages health care professionals to educate patients about risk factors associated with osteoporosis. In addition, the Society encourages health care professionals to identify and triage at-risk patients for osteoporosis screening and diagnosis. ASHP believes that patients at risk for osteoporosis and medical complications related to osteoporosis should receive an assessment of bone mineral density (BMD) by central dual-energy x-ray absorptiometry (DEXA) and both nonpharmacologic and pharmacologic therapy to prevent further bone loss and promote increased bone quality. Pharmacists may be well suited to provide osteoporosis screenings us-

ing peripheral devices and offer patient education regarding osteoporosis prevention and treatment,<sup>31-35</sup> though central DEXA is required for diagnosis.<sup>36</sup>


## Background

Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue. Low bone mass may be due to either increased loss of bone or failure to achieve sufficient peak bone mass.<sup>37</sup> A decline in bone mass due to advancing age, medications, or other risk factors increases bone fragility and susceptibility to fractures, especially at the hip, spine, forearm, and wrist.

The World Health Organization (WHO) defines osteoporosis as a BMD of 2.5 or more standard deviations below that of a normal young adult (t score of  $\leq -2.5$ ) for postmenopausal women and men over age 50 years as measured by central DEXA.<sup>3,38</sup> Osteopenia is defined as a BMD between  $-1$  and  $-2.5$  standard deviations below the young adult mean; a normal BMD value is defined as within 1 standard deviation of the mean BMD for a young adult. Patients who have a t score of  $\leq -2.5$  and have already had one or more fractures are classified as having severe or established osteoporosis. Figure 1 shows the distribution of BMD in healthy women age 30-40 years.<sup>36</sup>

Osteoporosis is a major public health problem in the United States. In 2002, over 10 million individuals had known osteoporosis, 80% of whom were women.<sup>39,40</sup> Approximately 44 million men and women over age 50 years have either os-

**Figure 1.** Distribution of bone mineral density in healthy women age 30-40 years. Reproduced from reference 36, with permission.



teoporosis or low BMD. If these trends continue, this figure may increase to over 61 million by 2020.<sup>39</sup>

Osteoporotic fractures are associated with significant morbidity and mortality. Patients who sustain a fracture are more likely to have lower health-related quality of life, depression, pain, disability, physical deconditioning due to inactivity, vertebral deformities with a resultant decrease in pulmonary function and increase in gastrointestinal complications (e.g., refractory reflux esophagitis), pressure ulcers, increased likelihood of nursing home placement, and changes in self-image.<sup>41–51</sup> Hip fractures, which are the most serious complication of osteoporosis, are associated with significant mortality.<sup>52–55</sup> Up to 38% of patients may die within one year after a hip fracture, and the risk of death is approximately double that of patients who do not sustain a hip fracture.<sup>52,53,55</sup>

The economic consequences of osteoporosis are enormous. In 1995, osteoporotic fractures were responsible for approximately 432,000 hospital admissions, 2.5 million physician's office visits, and 180,000 nursing home admissions.<sup>1</sup> Health care costs associated with osteoporotic fractures in 2001 were an estimated \$17 billion. As the population of the United States continues to age, these costs will likely increase, with the number of hip fractures and associated costs possibly tripling by 2040.<sup>1</sup>

Despite the significant morbidity, mortality, and economic consequences of osteoporosis and resultant fractures, many patients are not screened or treated. In a study of 3812 women with an average age of 71 years who sustained a new fragility (i.e., minimal-trauma) fracture, only 11.7% had a diagnosis of osteoporosis before the index fracture, and only 46.4% were managed as specified by clinical guidelines.<sup>5</sup> In another study of patients who sustained a fragility fracture, few patients received densitometry testing either before (13%) or after (22.2%) the index fracture.<sup>4</sup> Only 18.5% were diagnosed with osteoporosis, and only 32.4% received calcium supplementation. Thus, significant improvements must be made in the diagnosis and treatment of osteoporosis.

## Risk Assessment

Osteoporosis risk factor analysis is useful to identify patients at high risk of fractures, raise awareness of osteoporosis, promote strategies for prevention of fractures, and stimulate osteoporosis treatment (Table 1).<sup>1,3,56</sup> Prior fragility fracture as an adult and low BMD in patients with or without fractures are the two most important risk factors, both of which are clear indications for additional evaluation and possible therapeutic intervention.<sup>3</sup> Additional risk factors are listed in Table 1. ASHP encourages osteoporosis screening by all health care professionals, with specific attention to patients taking medications associated with decreased bone mass, including glucocorticosteroids, anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine), immunosuppressants, and excessive thyroid supplementation.<sup>1</sup>

ASHP believes health care professionals should conduct fall-risk assessment in conjunction with osteoporosis screening. All high-risk or elderly patients should be routinely asked about falls in the past year.<sup>57</sup> Older persons reporting a single fall should be assessed for balance and gait to detect balance problems.<sup>57,58</sup> Older persons who report recurrent falls or have gait or balance abnormalities will ben-

efit from a comprehensive fall evaluation.<sup>57</sup> Most patients demonstrate multiple risk factors for falls; common risk factors include muscle weakness, use of assistive devices, visual deficits, use of certain medications, arthritis, impaired activities of daily living, depression, cognitive impairment, and age greater than 80 years.<sup>57</sup> Three risk factors—hip weakness, unstable balance, and use of four or more medications—are highly predictive for one-year fall risk.<sup>59</sup> ASHP encourages a comprehensive drug regimen review to identify medications or drug-related problems that may increase fall risk. Medications commonly associated with increased falls include psychotropics, cardiovascular medications, and central nervous system agents.<sup>57,60,61</sup>

## Evaluation

Patients at risk for osteoporosis and related fractures should receive BMD testing by central DEXA. These patients include women age 65 years or older (regardless of risk factors), postmenopausal women under age 65 years with risk factors (Table 1), and postmenopausal women with a history of non-traumatic fracture. In addition, testing should be considered for men age 70 years or older, for patients with diseases that may result in decreased bone strength, for patients taking long-term medications known to decrease BMD, and to assess response in patients receiving medications for the treatment of osteoporosis. These recommendations are consistent

Table 1.

### Risk Factors for Osteoporosis and Related Fractures<sup>1,3,57</sup>

- Personal history of minimal-trauma fracture as an adult<sup>a</sup>
- History of fragility fracture in a first-degree relative<sup>a</sup>
- Low body weight (e.g., <127 lb)<sup>a</sup>
- Current smoking<sup>a</sup>
- Use of oral corticosteroid therapy for more than three months<sup>a</sup>
- Female sex
- Caucasian race
- Low physical activity
- Late menarche or early menopause
- Hypogonadism
- Low lifelong calcium intake
- Vitamin D deficiency
- Weight loss
- Impaired vision
- Dementia
- Poor health or frailty
- Recent falls
- Consumption of more than two alcoholic drinks per day
- Use of medications associated with falls (e.g., psychotropics, cardiovascular medications, central nervous system agents)
- Other medications with adverse bone effects (e.g., anticonvulsants, long-term heparin, immunosuppressants)
- Hyperthyroidism
- Hyperparathyroidism
- Renal hypercalciuria
- Chronic kidney or liver disease
- Gastrointestinal abnormalities (e.g., malnutrition, malabsorption, maldigestion)
- Rheumatoid arthritis
- Weightlessness

<sup>a</sup>Major risk factors in Caucasian postmenopausal women.<sup>1</sup>

with those of the National Osteoporosis Foundation (NOF), the American Association of Clinical Endocrinologists, and the U.S. Preventative Services Task Force.<sup>1,3,62</sup> While these recommendations may be considered broad, the use of validated risk assessments, such as SCORE (Simple Calculated Osteoporosis Risk Assessment) and ORAI (Osteoporosis Risk Assessment Instrument), may be useful in identifying women likely to have osteoporosis, thereby decreasing the number of women who undergo unnecessary central DEXA testing.<sup>63-65</sup> Further, a WHO working group in collaboration with the International Osteoporosis Foundation and NOF is developing and validating a new risk assessment tool.<sup>66</sup> This tool will use independent risk factors to calculate fracture probability, with or without the use of BMD, allowing treatment to be recommended for those with a fracture probability above the threshold for treatment.<sup>67</sup> A risk-assessment tool for use in men is discussed later in this document.

Currently, measurement of BMD by central DEXA is considered the gold standard for diagnosing osteoporosis, as it correlates significantly with the risk of fractures.<sup>62,68,69</sup> For each standard deviation decrease in femoral neck BMD, there is an approximate 2.5-fold increased risk of hip fracture.<sup>70,71</sup> Advantages of central DEXA include high sensitivity and specificity and the ability to measure BMD at numerous areas, including the hip, spine, and wrist. Disadvantages of central DEXA for mass screenings include equipment size and lack of portability, need for a dedicated room, expense, ionizing radiation, need for a radiation-certified and trained technician, lack of measurement of structure, and significant time required to screen and read the results.

Peripheral bone densitometers may be an ideal choice for mass screening and for assessing fracture risk.<sup>68</sup> These machines are generally much smaller and portable, require significantly less time to screen and read results, are available in models that use ultrasound rather than radiation, and have been shown to predict fracture risk.<sup>72</sup> Though useful in screening and identifying at-risk patients, peripheral bone densitometers should not be used as the primary tool for diagnosis or for monitoring treatment response due to their inability to measure BMD at all sites and the possibility of false-negative results.

## Prevention and Treatment

**Nonpharmacologic Therapies.** Several nonpharmacologic interventions for the prevention of osteoporotic fractures should be considered for all patients. The attainment of high peak bone mass early in life is one of the most important protective factors against reduced BMD later in life.<sup>2</sup> In addition, strategies to maintain current bone mass for patients in later stages of life should be instituted. Thus, appropriate weight-bearing exercise, minimization or elimination of various modifiable risk factors (e.g., smoking, excessive alcohol intake, maintenance of euthyroid status), and maintenance of adequate calcium and vitamin D intake should be recommended for all patients.<sup>1-3,37</sup>

Adequate calcium and vitamin D intake is considered an essential component of osteoporosis prevention and treatment,<sup>1-3,37</sup> yet many men and women over age 65 years consume only 600 mg of calcium daily. However, there is controversy regarding calcium and vitamin D supplementation. There is no universal consensus for the most appropriate daily dose (Table 2), though all groups recommend at least 1000 mg, and data are lacking regarding the most effective calcium salt. In addition, questions have been raised about the efficacy of calcium and vitamin D for prevention of fractures.

Several randomized controlled trials found that supplemental calcium or vitamin D<sub>3</sub> or both were effective in decreasing the risk for fractures.<sup>12-16</sup> In a primary prevention study of 3270 healthy postmenopausal women (mean age, 84 years), 1200 mg of elemental calcium (as the tricalcium phosphate) plus 800 IU of vitamin D given daily for 18 months was associated with a 43% decrease in the risk of hip fractures (number needed to treat [NNT] = 56,  $p = 0.043$ ) and a 32% decrease in nonvertebral fractures (NNT = 29,  $p = 0.015$ ).<sup>12</sup> In a primary prevention study of 389 ambulatory men and women over age 65 years, 500 mg of calcium (as calcium citrate) plus 700 IU of vitamin D<sub>3</sub> given daily for three years decreased the risk of nonvertebral fractures by 50% (NNT = 14; 95% confidence interval [CI], 0.2-0.9;  $p = 0.02$ ).<sup>13</sup>

However, two more recently published studies appear to contradict previous findings. In the Randomized

Table 2.

### Recommended Daily Dietary Reference Intakes of Elemental Calcium and Vitamin D<sup>a</sup>

| Supplement        | National Academy of Sciences <sup>73-75</sup> | National Osteoporosis Foundation <sup>1</sup> | NIH Consensus Panel <sup>76</sup>                           |
|-------------------|---|---|---|
| Elemental calcium | Age 31-50 yr: 1000 mg                         | Age <50 yr: 1000 mg                           | Age 25-65 yr and women >50 yr receiving estrogen: 1000 mg   |
|                   | Age >50 yr: 1200 mg                           | Age ≥50 yr: 1200 mg                           | Age >65 yr and women >50 yr not receiving estrogen: 1500 mg |
| Vitamin D         | Age 31-50 yr: 200 IU                          | Age <50 yr: 400-800 IU                        | ... <sup>b</sup>  |
|                   | Age 50-70 yr: 400 IU                          | Age ≥50 yr: 800-1000 IU                       |   |
|                   | Age >70 yr: 600 IU                            |   |   |

<sup>a</sup>Recommendations are for both men and women unless otherwise stated. NIH = National Institutes of Health.

<sup>b</sup>The NIH consensus panel does not provide recommendations for vitamin D supplementation.

Evaluation of Calcium or Vitamin D (RECORD) secondary prevention study, 5,292 elderly patients (mean age, 77 years) who had a low-trauma, osteoporotic fracture in the previous 10 years were randomized to receive 1000 mg calcium (as the carbonate), 800 IU of vitamin D<sub>3</sub>, the combination, or placebo.<sup>77</sup> After a median follow-up of 45 months, there was no significant difference in the rate of new low-trauma fractures ( $p > 0.05$  for all active treatments versus placebo). A significant limitation of this study was a low adherence rate at 24 months based on mailed questionnaires (60% adherence based on returned questionnaires, 47% adherence assuming nonresponders were nonadherent). Likewise, in the Women's Health Initiative (WHI) Calcium with Vitamin D Trial, which evaluated the effect of calcium and vitamin D supplementation on the frequency of hip and other bone fractures, 1000 mg calcium (as the carbonate) plus 400 IU of vitamin D given daily failed to reduce the risk of hip fracture, clinical spine fracture, or total fracture in 36,282 healthy postmenopausal women over seven years of use and increased the risk of renal calculi (number needed to harm [NNH] = 273).<sup>78</sup> There are several possible explanations for this lack of benefit, including the relatively low daily dose of vitamin D used, the fact that most patients did not have low BMD at baseline (mean hip t score,  $-0.65$  in subgroup for whom BMD was measured), and a possible lack of power attributable to a lower-than-expected hip fracture rate. In patients who adhered to therapy at least 80% of the time, fractures were reduced by 29%.

The results of a meta-analysis of double-blind, randomized controlled trials of patients over age 60 years suggest that vitamin D dosages of 700–800 IU daily with or without calcium reduced the risk for hip fracture and any nonvertebral fracture by 26% (NNT = 45) and 23% (NNT = 27), respectively, versus calcium alone or placebo.<sup>79</sup> However, no significant fracture reduction was seen with low daily doses (400 IU) of vitamin D.

In 2007, a large meta-analysis of more than 63,000 patients in 29 randomized trials found good evidence that the use of calcium, alone or in combination with vitamin D, prevented osteoporosis in women and men age 50 years and older.<sup>17</sup> This study also showed a 12% reduction in the risk of fractures, with treatment being more effective at higher doses of calcium (>1200 mg) and vitamin D (>800 IU).

Based on available evidence, NOF in July 2007 updated its recommendations for daily adequate calcium and vitamin D intake to provide 1000 mg of elemental calcium and 400–800 IU of vitamin D daily for adults under age 50 years and 1200 mg of elemental calcium and 800–1000 IU of vitamin D daily for adults age 50 years or older.<sup>73</sup> These recommended doses should be taken in two or three divided doses daily and used in addition to other nonpharmacologic modalities. Specific dosing recommendations provided by the National Academy of Sciences, NOF, and the National Institutes of Health Consensus Panel are outlined in Table 2. It is important to note that all studies assessing osteoporosis medications included calcium and vitamin D as background therapy. Thus, for patients with osteoporosis or who are at high risk of developing osteoporosis (e.g., patients with osteopenia; those with prior vertebral, nonvertebral, or hip fracture; patients with a history of long-term systemic corticosteroid use), use of an antiresorptive or anabolic agent in addition to nonpharmacologic modalities and calcium and vitamin D supplementation should be considered.

**Pharmacologic Therapies.** A wide range of medications are used in the prevention and treatment of osteoporosis (Table 3). In addition to bisphosphonates, which are the primary treatment approach, other therapies, such as calcitonin, estrogen-replacement therapies or estrogen-receptor modulators, and teriparatide, are approved by the Food and Drug Administration (FDA) for the prevention or treatment of osteoporosis. Several other therapies are currently under investigation (Table 4).

**Bisphosphonates.** The bisphosphonates alendronate, risedronate, ibandronate, and zoledronic acid are nitrogen-containing compounds that increase BMD by inhibiting osteoclast-mediated bone resorption.<sup>76</sup> They have been shown to increase BMD approximately 2–8%, depending upon the dose and site measured, and have demonstrated efficacy in primary and secondary prevention of osteoporotic fractures.<sup>18–25</sup>

In the Fracture Intervention Trials (FIT), the effects of alendronate in patients with and without vertebral fractures were evaluated. In the arm that included patients without vertebral fractures, 4432 women (mean age 68 years) who had low BMD (mean t score,  $-0.6$ ) with no history of vertebral fracture were randomized to receive either alendronate 5 mg for two years followed by 10 mg for two years or placebo.<sup>18</sup> After a mean follow-up of 4.2 years, women treated with alendronate demonstrated a 14% decrease in the rate of new clinical fractures, but this decrease was not statistically significant (hazard ratio [HR] = 0.86; 95% CI, 0.73–1.01). However, in patients with a femoral t score of  $<-2.5$ , the rate of clinical fractures was reduced by 36% (NNT = 15; 95% CI, 0.50–0.82) and clinical vertebral fractures decreased by 50% (NNT = 34; 95% CI, 0.31–0.82). Of the women who had at least one vertebral fracture ( $n = 2027$ ), alendronate decreased the rate of clinical fractures by 55% at the vertebrae (NNT = 37; 95% CI, 0.27–0.72), by 51% at the hip (NNT = 91; 95% CI, 0.23–0.99), and by 48% at the wrist (NNT = 53; 95% CI, 0.31–0.87).<sup>19</sup>

Risedronate has also been associated with a decreased risk of vertebral, nonvertebral, and hip fractures. In the Vertebral Efficacy with Risedronate Therapy in North America (VERT-NA) and Vertebral Efficacy with Risedronate Therapy—Multinational (VERT-MN) studies, risedronate sodium 2.5 and 5 mg daily were compared with placebo in ambulatory postmenopausal women with at least one vertebral fracture.<sup>20,21</sup> The 2.5-mg treatment option was discontinued after one year in the VERT-NA study and after two years in the VERT-MN study. After three years, the rate of new vertebral fractures decreased in risedronate-treated women by 41% in VERT-NA (NNT = 20; 95% CI, 0.18–0.58;  $p = 0.003$ ) and by 49% in VERT-MN (NNT = 10; 95% CI, 0.66–0.73;  $p < 0.001$ ); nonvertebral fractures decreased by 39% (NNT = 31; 95% CI, 0.06–0.61;  $p = 0.02$ ) and 33% (95% CI, 0.44–1.04;  $p = 0.063$ ) in the VERT-NA and VERT-MN studies, respectively. In another study specifically designed to assess hip-fracture prevention, women age 70–79 years with confirmed osteoporosis (mean femoral neck t score,  $-3.7$ ) or women age 80 years or older with at least one clinical risk factor were randomized to receive either risedronate sodium 2.5 or 5 mg daily or placebo. After three years, risedronate decreased the overall risk of hip fracture by 30% (NNT = 91; 95% CI, 0.6–0.9;  $p = 0.02$ ). However, this effect was limited only to women age 70–79 years who had confirmed osteoporosis (relative risk [RR] =

Table 3.

**Medications Used in the Management of Postmenopausal Osteoporosis**

| Agent                        | Labeled Indications   | Typical Dosage   | Fracture Reduction Data Available |                         |                         |
|------------------------------|---|--|-----------------------------------|-------------------------|-------------------------|
|                              |   |  | Vertebral                         | Nonvertebral            | Hip                     |
| Bisphosphonates <sup>a</sup> |   |  |                                   |                         |                         |
| Alendronate                  | Prevention and treatment <sup>80</sup>                          | 10 mg p.o. daily or 70 mg p.o. weekly <sup>b</sup>   | Yes <sup>18,19</sup>              | Yes <sup>19</sup>       | Yes <sup>19</sup>       |
| Ibandronate                  | Prevention and treatment <sup>81,82</sup>                       | 2.5 mg p.o. daily or 150 mg p.o. monthly   | Yes <sup>23</sup>                 | No                      | No                      |
| Risedronate                  | Prevention and treatment <sup>83</sup>                          | 3 mg i.v. every 3 mo<br>5 mg p.o. daily, 35 mg p.o. weekly, or 75 mg p.o. given on two consecutive days monthly (2 tablets/mo) | No<br>Yes <sup>20,21</sup>        | No<br>Yes <sup>20</sup> | No<br>Yes <sup>20</sup> |
| Zoledronic acid              | Treatment <sup>84</sup>   | 5 mg i.v. once yearly  | Yes <sup>24,25</sup>              | Yes <sup>24,25</sup>    | Yes <sup>25</sup>       |
| Calcitonin                   | Treatment <sup>85</sup>   | 1 spray (200 IU) intranasally, alternating nostrils daily  | Yes <sup>26</sup>                 | No                      | No                      |
| Estrogen-replacement therapy | Prevention <sup>86</sup>  | 0.625 mg conjugated estrogens p.o. daily   | Yes <sup>27,28</sup>              | Yes <sup>27,28</sup>    | Yes <sup>27,28</sup>    |
| Raloxifene                   | Prevention and treatment <sup>87</sup>                          | 60 mg p.o. daily   | Yes <sup>29</sup>                 | No                      | No                      |
| Teriparatide                 | Treatment in patients at high risk for fracture <sup>88,c</sup> | 20 µg s.c. daily   | Yes <sup>30</sup>                 | Yes <sup>30</sup>       | No                      |

<sup>a</sup>Alendronate and risedronate are approved for the treatment of osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease. Ibandronate and zoledronic acid injections are approved only for treatment in postmenopausal women.

<sup>b</sup>Dosage for treatment. May use 5 mg p.o. daily or 35 mg p.o. weekly for the prevention of osteoporosis.<sup>80</sup>

<sup>c</sup>Approved for the treatment of osteoporosis in men at high risk for fracture.

Table 4.

**Investigational Agents for the Treatment of Osteoporosis**

| Agent                              | Typical Dosage   | Fracture Reduction Data Available |                   |                     |
|------------------------------------|--|-----------------------------------|-------------------|---------------------|
|                                    |  | Vertebral                         | Nonvertebral      | Hip                 |
| Denosumab                          | 30 mg s.c. every 3 mo or 60 mg s.c. every 6 mo <sup>89</sup>               | No                                | No                | No                  |
| Parathyroid hormone 1-84           | 100 µg s.c. daily  | Yes <sup>90</sup>                 | No                | No                  |
| Sodium fluoride, sustained release | 25 mg p.o. b.i.d. for 12 mo, then 2-mo drug-free interval <sup>91,92</sup> | Yes <sup>91-93</sup>              | No                | No                  |
| Strontium ranelate                 | 2 g p.o. daily <sup>94,95</sup>  | Yes <sup>94,95</sup>              | Yes <sup>95</sup> | Yes <sup>95,a</sup> |

<sup>a</sup>Hip fracture reduction seen only in patients at high risk (age ≥74 years with femoral neck bone mineral density t score of ≤-3).

0.60; NNT = 77; 95% CI, 0.4–0.9;  $p = 0.009$ ), not in women selected primarily on the basis of clinical risk factors (RR = 0.80; 95% CI, 0.6–1.2;  $p = 0.35$ ).

Ibandronate is the newest oral bisphosphonate approved for the prevention and treatment of postmenopausal osteoporosis. In the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) of 2946 postmenopausal women (mean age, 69 years) with a BMD t score of -2.0 to -5.0 in at least one vertebra (L1-4), ibandronate sodium 2.5 mg daily or 20 mg every other day for 12 doses every three months for three years decreased the risk of new vertebral fractures by 62% (NNT = 20; 95% CI, 0.41–0.75;  $p = 0.0001$ ) and 50% (NNT = 21; 95% CI, 0.22–0.66;  $p = 0.0006$ ), respectively, compared with placebo.<sup>23</sup> There was no significant difference in the frequency of nonvertebral fractures (8.2%, 9.1%, and 8.9% for daily ibandronate, intermittent ibandronate, and placebo, respectively). However, baseline BMD at the proximal femur and femoral

neck was relatively high (mean t scores, -1.73 and -2.03, respectively) compared with that found in other studies.

The use of intermittent i.v. bisphosphonate infusions for osteoporosis has been investigated. Ibandronate sodium injection given as a 3-mg i.v. infusion once every three months was recently approved by FDA for the treatment of postmenopausal osteoporosis.<sup>80</sup> In the Phase III, randomized, double-dummy, Dosing Intravenous Administration (DIVA) study, ibandronate sodium injection given as a 3-mg i.v. infusion once every three months for one year to 1395 postmenopausal women (mean age, 66–67 years) increased BMD at the lumbar spine and total hip to a greater extent than did 2.5 mg given orally (4.8% versus 3.8% and 2.1% versus 1.5%, respectively) ( $p < 0.05$  for both comparisons).<sup>97</sup>

Zoledronic acid has also been found to increase BMD in a similar manner when given as an intermittent i.v. infusion.<sup>98</sup> In August 2007, zoledronic acid became the first bisphosphonate to receive FDA-approved labeling for once-

yearly administration in the treatment of osteoporosis in postmenopausal women.<sup>84</sup> Results of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial (PFT) demonstrated that a 5-mg i.v. infusion given once yearly for three years was effective in reducing the risk of new vertebral fractures by 70% (NNT = 13,  $p < 0.001$ ), hip fractures by 41% (NNT = 91,  $p = 0.002$ ), and nonvertebral fractures by 25% (NNT = 37,  $p < 0.001$ ).<sup>25</sup> While most adverse effects were similar between groups, atrial fibrillation was more common in those receiving zoledronic acid (20 versus 50 patients) (NNH = 125,  $p < 0.001$ ).

The subsequent HORIZON Recurrent Fracture Study assessing the effect of once-yearly zoledronic acid i.v. within 90 days after surgical repair of a hip fracture reduced the risk of any new clinical fracture by 35% (NNT = 19,  $p = 0.001$ ), new clinical vertebral fractures by 46% (NNT = 48,  $p = 0.02$ ), and new nonvertebral fractures by 27% (NNT = 32,  $p = 0.03$ ) compared to placebo.<sup>24</sup> There was no statistically significant reduction in hip fractures (2.0% versus 3.5%,  $p = 0.18$ ). However, mortality was reduced by 28% (NNT = 27,  $p = 0.01$ ). The rate of atrial fibrillation in the zoledronic acid group (1.1%) was similar to the placebo group (1.3%).

While administration of bisphosphonates for postmenopausal osteoporosis allows for intermittent dosing (i.e., 70 mg orally once weekly for alendronate, 35 mg orally once weekly or 75 mg orally given on two consecutive days once a month for risedronate, 150 mg orally every month or 3 mg i.v. every three months for ibandronate, and 5 mg i.v. once yearly for zoledronic acid), it is important to note that, with the exception of zoledronic acid, studies specifically designed to assess fracture equivalency are lacking. Data demonstrating equivalency of BMD effects for oral intermittent and daily dosing are available.<sup>99–101</sup> Thus, intermittent regimens may be advocated, as they are likely to have similar efficacy regarding fracture reduction and have the potential to increase adherence and improve gastrointestinal tolerability,<sup>102,103</sup> though future studies are needed to confirm these benefits. In addition, while other bisphosphonates with a variety of indications are available (e.g., etidronate, pamidronate, tiludronate), these agents lack data demonstrating fracture reduction in postmenopausal osteoporosis and should not be used as a first-line treatment for this indication.

The long-term bone safety of bisphosphonates has recently been questioned. Unusual fractures and delayed healing, possibly due to oversuppression of bone turnover, have been reported.<sup>103,105</sup> In addition, there have been highly publicized cases of osteonecrosis of the jaw.<sup>106</sup> However, it is important to note that the majority of cases have occurred with i.v. bisphosphonates in patients with multiple myeloma and metastatic cancer of the skeleton, where the dosages used are considerably higher than those used for osteoporosis.<sup>106</sup> Thus, it is not known whether patients using bisphosphonates for the prevention or treatment of osteoporosis are at significant increased risk. In addition, long-term studies of alendronate and risedronate have not demonstrated these adverse effects.<sup>107,108</sup> Considering the increasing use of these agents, continued monitoring for potential adverse bone effects should be advocated.

**Calcitonin.** Calcitonin is a 32-amino-acid peptide that inhibits osteoclast-mediated bone resorption.<sup>109</sup> The salmon form is approximately 40-fold more potent than the human form, due to conformational flexibility.<sup>110</sup> Data are available

that support the use of salmon calcitonin for treatment of vertebral fractures in women with osteoporosis, though nonvertebral fracture data are generally lacking. In the Prevent Recurrence of Osteoporotic Fractures (PROOF) study, intranasal salmon calcitonin (100, 200, or 400 IU daily) was compared with placebo in 1255 postmenopausal women with preexisting vertebral compression fractures.<sup>26</sup> After five years of follow-up, 200 IU of salmon calcitonin daily was associated with a 33% decrease in the rate of new vertebral fractures (NNT = 13; RR = 0.67; 95% CI, 0.47–0.97;  $p = 0.03$ ). No significant differences in the rate of new vertebral fractures were demonstrated in patients taking 100 or 400 IU of salmon calcitonin. One factor that may have limited the findings of this study was the high dropout rate. Fifty-nine percent of patients withdrew from the study early, though rates of discontinuation were similar in all treatment groups. In addition to the ability to prevent future vertebral fractures, salmon calcitonin also appears to possess analgesic activity.<sup>111,112</sup> Thus, this agent may be useful in the treatment of acute vertebral fractures, in which back pain can be significant.

**Estrogen.** Although estrogen-replacement therapy (ERT) was used as an antiresorptive therapy for many years for the prevention or treatment of osteoporosis, there was a paucity of data from clinical trials demonstrating a reduction in the risk of fractures, particularly at the hip. Previous recommendations for routine use of estrogen were based on observational studies and meta-analyses that indicated an approximate 30–60% reduction in vertebral and nonvertebral fractures with five or more years of ERT use.<sup>113–116</sup>

With the publication of the results of the WHI study, guidelines for ERT have significantly changed, now recommending against the use of ERT solely to prevent osteoporosis and encouraging the use of alternative therapies first.<sup>1,3</sup> The WHI study was the largest randomized, prospective trial to evaluate the risks and benefits of estrogen with and without a progestin in healthy postmenopausal women. The estrogen plus progestin group included 16,608 women with an intact uterus who received either 0.625 mg of conjugated equine estrogen (CEE) plus 2.5 mg of medroxyprogesterone acetate or placebo.<sup>27</sup> The estrogen-only group included 10,739 women with a prior hysterectomy who received 0.625 mg of CEE daily or placebo.<sup>28</sup> After an average follow-up of 5.2 years, estrogen plus progestin was discontinued due to a slightly increased risk of breast cancer (NNH = 237). In addition, investigators found that these women had a small increase in the risk of coronary heart disease (CHD) (NNH = 237), pulmonary embolism (NNH = 227), stroke (NNH = 225), and deep venous thrombosis (NNH = 141). There was a slight decrease in the risk of hip fracture (NNT = 345), clinical vertebral fracture (NNT = 387), and lower arm or wrist fracture (NNT = 125).<sup>117</sup> Likewise, estrogen-only therapy was discontinued after a mean follow-up of 6.8 years due to lack of benefit for the primary outcome of CHD and an increased risk of stroke (NNH = 125). While the estrogen-only group did have an increased risk of deep venous thrombosis (NNH = 220), there was no increased risk of pulmonary embolism or breast cancer. CEE alone did decrease the risk of hip and vertebral fractures slightly (NNT = 216 and NNT = 225, respectively).

Based on the results of the WHI study, estrogen should not be used to prevent CHD or as first-line therapy for postmenopausal osteoporosis and should generally be

used at the lowest therapeutic dosage for the shortest time possible to control significant menopausal symptoms (e.g., hot flashes).<sup>27,28,118</sup> Strong consideration of other medications that have been shown to decrease the risk of fractures and weighing of the risks and benefits are recommended before using estrogen solely to prevent osteoporosis.

**Raloxifene.** Raloxifene is a selective estrogen receptor modulator that has estrogenic effects on some tissues (e.g., bone [ $\approx 2\text{--}3\%$  increase in BMD depending on dosage and site measured], lipid metabolism, clotting cascade) while having antiestrogenic effects on others (e.g., uterine endometrium, breast tissue).<sup>29,119</sup> Data are available that support the use of raloxifene for the treatment of osteoporosis. In the Multiple Outcomes of Raloxifene Evaluation (MORE), 7705 postmenopausal women (mean age, 67 years) with osteoporosis were randomized to receive raloxifene 60 mg daily, raloxifene 120 mg daily, or placebo.<sup>29</sup> After 36 months, the use of raloxifene 60 and 120 mg daily was associated with a 30% and 50% decrease in the rate of new vertebral fractures, respectively (NNT = 29; 95% CI, 0.5–0.8 and NNT = 21; 95% CI, 0.4–0.7). There was no significant difference in the rate of nonvertebral fractures (RR = 0.9; 95% CI, 0.8–1.1). Importantly, raloxifene increased the rate of venous thromboembolism (NNH = 143; 95% CI, 1.5–6.2). Raloxifene was not associated with vaginal bleeding or breast pain, and patients who took the drug had a lower incidence of breast cancer than women who received placebo (RR = 0.3; 95% CI, 0.2–0.6). However, hot flashes were more common in the raloxifene group (9.7% and 11.7% for the 60- and 120-mg dosages, respectively, versus 6.5% for placebo).

The role of raloxifene in the management of osteoporosis may be further elucidated with the publication of two recent studies. The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 study was a prospective, double-blind, randomized trial of 19,247 postmenopausal women (mean age, 58.5 years) with an increased risk of breast cancer (mean risk, 4.03%).<sup>120</sup> After a mean follow-up of 3.9 years, raloxifene 60 mg daily was shown to be as effective as tamoxifen in decreasing the risk of invasive breast cancer (168 cases with raloxifene versus 163 cases with tamoxifen) (RR = 1.02; 95% CI, 0.82–1.28). The Raloxifene for Use of the Heart (RUTH) study, a prospective, double-blind, randomized trial of 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD, was designed to assess the effects of raloxifene 60 mg daily on cardiovascular disease.<sup>121</sup> After a median follow-up of 5.6 years, raloxifene did not decrease the risk of the primary outcome of death from coronary causes, myocardial infarction, or hospitalization for acute coronary syndrome (HR = 0.95; 95% CI, 0.84–1.07) or stroke (HR = 1.10; 95% CI, 0.92–1.32), though it did increase the risk of venous thromboembolism (NNH = 157) and fatal stroke (NNH = 251). Similar to other studies, raloxifene did decrease the risk of clinical vertebral fractures (NNT = 154), noninvasive breast cancer (NNT = 169), estrogen-receptor positive breast cancer (NNT = 169), and death from noncardiovascular and noncancer causes (NNT = 118 and NNT = 138, respectively).

The use of raloxifene for the management of osteoporosis should be based on a risk–benefit assessment. It may be an ideal choice for women who have contraindications to or do not tolerate a bisphosphonate, are not experiencing vasomotor symptoms, and do not have CHD or multiple risk

factors for CHD. In addition, it may be particularly appealing for patients at high risk for breast cancer.

**Teriparatide.** Teriparatide, a recombinant form of parathyroid hormone (PTH 1-34), may increase or decrease BMD, depending on the route of administration. Given as an exogenous, intermittent injection, teriparatide increases BMD by stimulating bone formation.<sup>122</sup> The effects of teriparatide in postmenopausal women with prior vertebral fractures have been evaluated. In a placebo-controlled study of 1637 postmenopausal women (mean age, 69 years) with at least one prior vertebral fracture 20 and 40  $\mu\text{g}$  of teriparatide given daily by subcutaneous injection decreased the rate of new vertebral fractures by 65% and 69%, respectively (NNT = 11 and NNT = 10).<sup>30</sup> In addition, new nonvertebral fragility fractures were decreased 53% and 54% for the 20- and 40- $\mu\text{g}$  groups, respectively (NNT = 33 for both treatment groups).

Data from rat carcinogenicity studies have suggested a possible increased risk of osteosarcomas associated with the use of PTH 1-34 analogues.<sup>122</sup> Thus, teriparatide should not be used in patients who have an increased risk of developing osteosarcomas (e.g., those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, or prior external beam or implant radiation therapy involving the skeleton), and administration should be limited to two years' use.<sup>88</sup> In addition, due to significant costs ( $\approx \$850$  per month<sup>123</sup>) and the need for daily injections, teriparatide should only be used in patients with established osteoporosis who have a high risk of future fractures or who are intolerant to or have contraindications to both bisphosphonates and raloxifene.

**Combination therapies.** There are limited data supporting the use of combination antiresorptive treatments for osteoporosis. While data are available demonstrating greater increases in BMD with the use of estrogen or raloxifene in combination with a bisphosphonate,<sup>124–127</sup> fracture data are lacking. In addition, the use of a bisphosphonate with PTH 1-84 or PTH 1-34 may result in attenuation of the anabolic effects of PTH,<sup>128,129</sup> though sequential treatment with a bisphosphonate after therapy with PTH 1-84 appears to maintain or increase BMD gains.<sup>130</sup> Thus, until fracture outcomes data are available, concurrent combination therapy should generally be avoided or used with caution by an osteoporosis specialist.

**Investigational treatments.** Denosumab is a monoclonal antibody to the receptor activator for nuclear factor- $\kappa$ B ligand (RANKL) that mimics osteoprotegerin and decreases bone resorption through inhibition of osteoclast differential, activation, and survival.<sup>131</sup> In a recent Phase II study, the safety and efficacy of denosumab were assessed in 412 postmenopausal women (mean age, 63 years) with low BMD (mean lumbar t score,  $-2.0$  to  $-2.3$ ; mean femoral neck t score,  $-1.7$  to  $-2.0$ ).<sup>89</sup> Patients were randomized to receive subcutaneous denosumab every 3 months (doses of 6, 14, or 30 mg), every 6 months (doses of 14, 16, or 30 mg), open-label alendronate sodium 70 mg p.o. weekly, or placebo. After 12 months of treatment, denosumab increased BMD at the lumbar spine by 3.0–6.7% (versus 4.8% with alendronate and  $-0.8\%$  with placebo [ $p < 0.001$  for comparison of denosumab with placebo]) and total hip by 1.9–3.6% (versus 2.1% with alendronate and  $-0.6\%$  with placebo [ $p < 0.001$  for comparison of denosumab with placebo]). Thus, denosumab holds promise as a future agent and may be particularly appealing from an adherence standpoint, though data regarding its ability to protect against fractures are needed.

PTH 1-84 is the full-length 84-amino acid PTH that was approved in April 2006 in the European Union for treatment of osteoporosis in postmenopausal women at high risk for fracture<sup>132</sup> and has received an approvable letter from FDA.<sup>133</sup> In the randomized, double-blind, placebo-controlled, Phase III Treatment of Osteoporosis with PTH (TOP) trial, 100  $\mu$ g of PTH 1-84 was given subcutaneously once daily to 2532 postmenopausal women with osteoporosis (mean t score,  $-3.0$ ), 19% of whom had experienced a prior vertebral fracture.<sup>90</sup> After a median of 18 months, PTH 1-84 decreased the risk of new vertebral fractures by 61% (NNT = 48,  $p = 0.001$ ). There was no difference in the incidence of any nonvertebral fracture (5.52% for PTH 1-84 versus 5.86% for placebo).<sup>134</sup> In a recent international, multicenter, double-blind, randomized, parallel group trial of 2532 postmenopausal women with osteoporosis with and without prior fractures, 100  $\mu$ g of PTH 1-84 given subcutaneously daily was compared with placebo.<sup>135</sup> After 18 months, PTH 1-84 decreased the risk of new or worsened vertebral fractures by 60% (NNT = 50,  $p = 0.001$ ) in a modified intent-to-treat analysis, though this rate change was based on assumptions of fracture rates for those who withdrew early from the study. Adverse effects that were more common in the group treated with PTH 1-84 than in the placebo group included hypercalciuria (46.0% versus 22.3%, NNH = 4), hypercalcemia (27.8% versus 4.5%, NNH = 4), nausea (22.6% versus 9.2%, NNH = 7), and vomiting (7.7% versus 4.3%, NNH = 29). Thus, PTH 1-84 has potential as a future anabolic treatment for women at high risk for fracture, though comparative data with teriparatide (PTH 1-34) are needed to elucidate if any clinical differences in BMD or fracture efficacy exist between the full-length and shortened (i.e., PTH 1-34) versions.

Sodium fluoride is an anabolic agent that increases BMD by stimulating osteoblast activity.<sup>136,137</sup> While it has been available for many years and may be considered an alternative agent in Europe,<sup>56</sup> oral therapy has not been approved for use in the United States due to concerns regarding decreases in bone quality and strength, despite increases in BMD, and adverse effects such as gastrointestinal symptoms and lower-extremity pain.<sup>138</sup> These concerns may have been caused by higher doses and immediate-release formulations given on a continuous basis. While lower doses of a sustained-release formulation have been shown to increase BMD in vertebrae L2–L4 by 5.4% and decrease vertebral fractures by 68% (NNT = 8; 95% CI, 0.14–0.73;  $p = 0.007$ ), with no additional increases in gastrointestinal and musculoskeletal adverse effects,<sup>91</sup> it is doubtful this agent will be approved for use in the United States.

Strontium ranelate is an orally active di-strontium salt that has both anabolic and antiresorptive effects on bone.<sup>139</sup> It was approved in Europe in September 2004 for the treatment of postmenopausal osteoporosis<sup>140</sup> but is not yet approved for use in the United States. Strontium has been shown to decrease both vertebral and nonvertebral fractures. In a Phase III study of 1649 postmenopausal women with osteoporosis (mean age, 69 years) and at least one vertebral fracture, 2 g of strontium ranelate daily for three years decreased the rate of new vertebral fractures by 41% (NNT = 8; 95% CI, 0.48–0.73;  $p < 0.001$ ).<sup>94</sup> In the Treatment of Peripheral Osteoporosis Study (TROPOS), strontium ranelate 2 g daily for three years in 5091 postmenopausal women with osteoporosis (mean age, 77 years) decreased the rate for all

nonvertebral fractures by 16% and decreased the rate of major fragility fractures (i.e., hip, wrist, pelvis, sacrum, ribs and sternum, clavicle, and humerus) by 19% (NNT = 59 for both fracture types) versus placebo.<sup>95</sup> There was no significant difference in hip fractures in the intent-to-treat population, but, for those in the high-risk subgroup (age  $\geq 74$  years with femoral neck BMD t score of  $\leq -3$ ), there was a 36% reduction in fracture risk (NNT = 48; 95% CI, 0.412–0.997;  $p = 0.046$ ). Strontium ranelate has potential as a future treatment in the United States for osteoporosis, though it remains to be seen if this agent will be brought to market.

**Special Populations. Nursing-home patients.** Approximately 80–85% of U.S. nursing-home residents suffer from osteoporosis.<sup>141</sup> Because nursing-home residents are often afflicted with multiple diseases, disabilities, and fragility, their fracture rates are much higher than the community-dwelling elderly. Other factors associated with the higher fracture rate among nursing-home residents include immobility, low body mass, difficulty transferring (e.g., moving from a bed to a wheelchair), falls, and multiple medications.<sup>142</sup> In addition, many nursing-home residents have inadequate nutritional status, including low intake of calcium and vitamin D as well as inadequate sunlight exposure.<sup>142,143</sup> Osteoporosis treatment for nursing-home residents ideally involves a multifactorial approach emphasizing fall prevention, adequate nutrition, strength and balance training, medication review, and environmental modifications (e.g., redesigning home environments, removal of floor rugs). While devices such as hip protectors have been shown to prevent fractures in patients at high risk,<sup>144</sup> more recent data indicated that these are ineffective interventions.<sup>145</sup> Underuse of osteoporosis diagnostic procedures in nursing-home residents is well documented.<sup>146</sup> Even when osteoporosis is diagnosed and documented in the medical record, few patients receive optimal therapy despite data demonstrating that screening and treatment are highly cost-effective.<sup>147</sup>

Calcium and vitamin D supplements are prescribed for approximately 60% of nursing-home residents with osteoporosis and only 25% of residents with hip fractures.<sup>148</sup> Similarly, bisphosphonate use among nursing-home residents with documented hip fractures approaches 25%.<sup>149</sup> Because the majority of nursing-home residents with osteoporosis receive inadequate drug therapy, ASHP urges interdisciplinary team approaches to detect and manage osteoporosis in this setting. Osteoporosis guidelines are useful and may be cost-effective, with implementation dependent on cooperation from the facility medical director, attending physicians, the director of nursing, therapists, and the consultant pharmacist.<sup>150</sup>

**Men.** Two million American men have osteoporosis and another 12 million are at risk for developing osteoporosis.<sup>151</sup> Thirty percent of hip fractures occur in men, and one in eight men over age 50 years will have an osteoporosis-related fracture in his lifetime.<sup>152</sup> Hip fracture-related mortality and morbidity are significantly greater in men than in women, with one-year mortality after hip fracture approximately double that of women.<sup>153</sup> After sustaining a hip fracture, up to 50% of men require institutional care.

Despite the serious consequences of hip fracture for men, osteoporosis has only recently received attention as a major men's health issue. There remain significant barriers, particularly reimbursement for screening. Medicare

will only cover screening costs for “qualified individuals”: estrogen-deficient women, individuals with vertebral abnormalities, those with known primary hyperparathyroidism, individuals receiving steroid therapy, and those receiving FDA-approved osteoporosis medications.<sup>154</sup> Risk factors associated with osteoporosis in men include hypogonadism associated with low testosterone and low estradiol, chronic diseases, chronic obstructive pulmonary disease, prolonged exposure to osteoporosis-inducing medications, Caucasian race, heredity, and advanced age.<sup>151,155</sup> Lifestyle may increase the risk of osteoporosis in men, including current smoking, excessive alcohol use, low calcium intake, and low physical activity. The Male Osteoporosis Risk Estimation Score, or MORES, has been developed as one approach to identify men age 60 years or older at risk for osteoporosis.<sup>156</sup> Those men found to be at risk should be referred for a DEXA scan. Osteoporosis treatment in men comprises calcium and vitamin D supplements; bisphosphonates; testosterone replacement, if indicated (i.e., hypogonadism); and teriparatide for men at high risk of fracture.<sup>1,129,157</sup>

### Summary

ASHP believes that patients at risk for osteoporosis and related fractures (e.g., women age 65 years or older regardless of risk factors, postmenopausal women under age 65 years with risk factors, postmenopausal women with a history of nontraumatic fracture, men with a significant risk of fracture) should receive appropriate risk assessment and evaluation of BMD using central DEXA. Patients with confirmed low BMD who are at risk for fractures should receive treatment. ASHP believes that medications shown to reduce the risk of fractures should be used. These include calcium and vitamin D for all patients, bisphosphonates, raloxifene, calcitonin, estrogen, and teriparatide. ASHP acknowledges that the choice of agent will depend on its ability to increase BMD and decrease fractures, as well as various patient-specific criteria (e.g., medical history, contraindications, patient beliefs or preferences, finances). In general, agents that have been shown to decrease vertebral, nonvertebral, and hip fractures should be used preferentially.

ASHP believes that clinicians need to be actively involved in educating both patients and collaborative health care professionals regarding risk factors associated with osteoporosis and fractures. Efforts should include recommendations for appropriate weight-bearing exercise, identification of agents that may decrease BMD (e.g., corticosteroids) or increase the risk for falls (e.g., long-acting benzodiazepines), and appropriate calcium and vitamin D intake. Well-designed clinical trials are needed to better assess who should be screened, compare various medications' effects on fracture rates, and better identify patients who should receive treatment with antiresorptives, anabolic agents, or combination therapy.

### References

1. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. [www.nof.org/physguide/index.htm](http://www.nof.org/physguide/index.htm) (accessed 2005 Mar 23).
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA*. 2001; 285:785–95.
3. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. *Endocr Pract*. 2003; 9:544–64. [Erratum, *Endocr Pract*. 2004; 10:90.]
4. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. *CMAJ*. 2000; 163:819–22.
5. Feldstein AC, Nichols GA, Elmer PJ et al. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. *J Bone Joint Surg Am*. 2003; 85-A:2294–302.
6. Andrade SE, Majumdar SR, Chan KA et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. *Arch Intern Med*. 2003; 163:2052–7.
7. Harrington JT, Broy SB, Derosa AM et al. Hip fracture patients are not treated for osteoporosis: a call to action. *Arthritis Rheum*. 2002; 47:651–4.
8. Solomon DH, Finkelstein JS, Katz JN et al. Underuse of osteoporosis medications in elderly patients with fractures. *Am J Med*. 2003; 115:398–400.
9. Adler GS, Shatto A. Screening for osteoporosis and colon cancer under Medicare. *Health Care Financ Rev*. 2002; 23:189–200.
10. National Committee for Quality Assurance. Osteoporosis management in women who had a fracture. In: The state of health care quality, 2005. [www.ncqa.org/Docs/SOHCQ\\_2005.pdf](http://www.ncqa.org/Docs/SOHCQ_2005.pdf) (accessed 2007 Nov 27).
11. Centers for Disease Control and Prevention and National Institutes of Health. Healthy People 2010: arthritis, osteoporosis, and chronic back conditions. [www.healthypeople.gov/Document/HTML/Volume1/02Arthritis.htm](http://www.healthypeople.gov/Document/HTML/Volume1/02Arthritis.htm) (accessed 2006 Jul 11).
12. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. *N Engl J Med*. 1992; 327:1637–42.
13. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med*. 1997; 337:670–6.
14. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. *J Bone Miner Res*. 2004; 19:370–8.
15. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ*. 2003; 326:469.
16. Tilyard MW, Spears GF, Thomson J et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. *N Engl J Med*. 1992; 326:357–62.
17. Tang BM, Eslick GD, Nowson C et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged

- 50 years and older: a meta-analysis. *Lancet*. 2007; 370:657–66.
18. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. *JAMA*. 1998; 280:2077–82.
  19. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet*. 1996; 348:1535–41.
  20. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. *JAMA*. 1999; 282:1344–52.
  21. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. *Osteoporos Int*. 2000; 11:83–91.
  22. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. *N Engl J Med*. 2001; 344:333–40.
  23. Chesnut IC, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *J Bone Miner Res*. 2004; 19:1241–9.
  24. Lyles KW, Colón-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med*. 2007; 357:1799–809.
  25. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med*. 2007; 356:1809–22.
  26. Chesnut CH 3rd, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence Of Osteoporotic Fractures Study. *Am J Med*. 2000; 109:267–76.
  27. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002; 288:321–33.
  28. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 2004; 291:1701–12.
  29. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. *JAMA*. 1999; 282:637–45.
  30. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med*. 2001; 344:1434–41.
  31. MacLaughlin EJ, MacLaughlin AA, Snella KA et al. Osteoporosis screening and education in community pharmacies using a team approach. *Pharmacotherapy*. 2005; 25:379–86.
  32. Goode JV, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project IMPACT: Osteoporosis. *J Am Pharm Assoc*. 2004; 44:152–60.
  33. Elliott ME, Meek PD, Kanous NL et al. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. *J Am Pharm Assoc*. 2002; 42:101–10.
  34. Lata PF, Binkley NC, Elliott ME. Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. *Menopause*. 2002; 9:449–55.
  35. Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. *J Am Pharm Assoc*. 2004; 44:161–7.
  36. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*. 2002; 359:1929–36.
  37. World Health Organization. Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO Expert Consultation. WHO technical report series no. 916. [http://whqlibdoc.who.int/trs/WHO\\_TRS\\_916.pdf](http://whqlibdoc.who.int/trs/WHO_TRS_916.pdf) (accessed 2007 Nov 1).
  38. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. *Osteoporos Int*. 2000; 11:192–202.
  39. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass, 2005. [www.nof.org/advocacy/prevalence/index.htm](http://www.nof.org/advocacy/prevalence/index.htm) (accessed 2007 Nov 28).
  40. National Osteoporosis Foundation. Fast facts. [www.nof.org/osteoporosis/diseasefacts.htm](http://www.nof.org/osteoporosis/diseasefacts.htm) (accessed 2005 Apr 22).
  41. Lips P, Cooper C, Agnusdei D et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). *Osteoporos Int*. 1999; 10:150–60.
  42. Gold DT, Shipp KM, Lyles KW. Managing patients with complications of osteoporosis. *Endocrinol Metab Clin North Am*. 1998; 27:485–96.
  43. Yamaguchi T, Sugimoto T, Yamauchi M et al. Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. *J Bone Miner Metab*. 2005; 23:36–40.
  44. Hallberg I, Rosenqvist AM, Kartous L et al. Health-related quality of life after osteoporotic fractures. *Osteoporos Int*. 2004; 15:834–41.
  45. Nevitt MC, Ettinger B, Black DM et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. *Ann Intern Med*. 1998; 128:793–800.
  46. Fink HA, Ensrud KE, Nelson DB et al. Disability after clinical fracture in postmenopausal women with low bone density: the Fracture Intervention Trial (FIT). *Osteoporos Int*. 2003; 14:69–76.
  47. Ensrud KE, Thompson DE, Cauley JA et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. *J Am Geriatr Soc*. 2000; 48:241–9.
  48. Margolis DJ, Knauss J, Bilker W et al. Medical conditions as risk factors for pressure ulcers in an outpatient setting. *Age Ageing*. 2003; 32:259–64.
  49. Melton LJ 3rd. Adverse outcomes of osteoporotic fractures in the general population. *J Bone Miner Res*. 2003; 18:1139–41.

50. Schlaich C, Minne HW, Bruckner T et al. Reduced pulmonary function in patients with spinal osteoporotic fractures. *Osteoporos Int*. 1998; 8:261–7.
51. Adachi JD, Ioannidis G, Olszynski WP et al. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. *BMC Musculoskelet Disord*. 2002; 3:11.
52. Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. *J Am Geriatr Soc*. 2004; 52:685–90.
53. Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. *Lancet*. 1999; 353:878–82.
54. Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clinical fractures. *Osteoporos Int*. 2000; 11:556–61.
55. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. *BMJ*. 1993; 307:1248–50.
56. New Europe Consensus on Osteoporosis. 2nd Central and Eastern European Regional Osteoporosis Meeting. [www.iofbonehealth.org/download/osteofound/file-manager/policy\\_advocacy/pdf/lacrima.pdf](http://www.iofbonehealth.org/download/osteofound/file-manager/policy_advocacy/pdf/lacrima.pdf) (accessed 2007 Nov 27).
57. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. *J Am Geriatr Soc*. 2001; 49:664–72.
58. Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc*. 1991; 39:142–8.
59. Robbins AS, Rubenstein LZ, Josephson KR et al. Predictors of falls among elderly people. Results of two population-based studies. *Arch Intern Med*. 1989; 149:1628–33.
60. Fick DM, Cooper JW, Wade WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. *Arch Intern Med*. 2003; 163:2716–24.
61. Sleeper RB, Bond C, Rojas-Fernandez C. Psychotropic drugs and falls: new evidence pertaining to SSRIs. *Pharmacotherapy*. 2000; 20:308–17.
62. Agency for Healthcare Research and Quality. Screening for osteoporosis in postmenopausal women: recommendations and rationale. [www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm](http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm) (accessed 2005 Apr 21).
63. Lydick E, Cook K, Turpin J et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. *Am J Manag Care*. 1998; 4:37–48.
64. Cadarette SM, Jaglal SB, Kreiger N et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. *CMAJ*. 2000; 162:1289–94.
65. Cadarette SM, Jaglal SB, Murray TM et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. *JAMA*. 2001; 286:57–63.
66. International Osteoporosis Foundation. WHO Working Group on Fracture Risk Assessment. [www.iofbonehealth.org/about-iof/partnerships/who.html](http://www.iofbonehealth.org/about-iof/partnerships/who.html) (accessed 2006 Jul 20).
67. Kanis JA, Borgstrom F, De Laet C et al. Assessment of fracture risk. *Osteoporos Int*. 2005; 16:581–9.
68. Lewiecki EM, Watts NB, McClung MR et al. Official positions of the International Society for Clinical Densitometry. *J Clin Endocrinol Metab*. 2004; 89:3651–5.
69. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. *JAMA*. 2002; 288:1889–97.
70. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. *Lancet*. 1993; 341:72–5.
71. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ*. 1996; 312:1254–9.
72. Siris ES, Miller PD, Barrett-Connor E et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. *JAMA*. 2001; 286:2815–22.
73. National Osteoporosis Foundation. National Osteoporosis Foundation’s updated recommendations for calcium and vitamin D intake. [www.nof.org/prevention/calcium\\_and\\_VitaminD.htm](http://www.nof.org/prevention/calcium_and_VitaminD.htm) (accessed 2007 Jul 31).
74. Institute of Medicine. Dietary reference intake tables: elements. [www.iom.edu/Object.File/Master/7/294/0.pdf](http://www.iom.edu/Object.File/Master/7/294/0.pdf) (accessed 2005 May 3).
75. Institute of Medicine. Dietary reference intake tables: vitamins. [www.iom.edu/Object.File/Master/7/296/0.pdf](http://www.iom.edu/Object.File/Master/7/296/0.pdf) (accessed 2005 May 3).
76. NIH Consensus Conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. *JAMA*. 1994; 272:1942–8.
77. Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet*. 2005; 365:1621–8.
78. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*. 2006; 354:669–83.
79. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA*. 2005; 293:2257–64.
80. Fosamax (alendronate) package insert. Whitehouse Station, NJ: Merck; 2004.
81. Boniva (ibandronate sodium) injection package insert. Nutley, NJ: Roche Laboratories; 2006.
82. Boniva (ibandronate sodium) package insert. Nutley, NJ: Roche Laboratories; 2005.
83. Actonel (risedronate) package insert. Cincinnati: Procter & Gamble Pharmaceuticals; 2007.
84. Reclast (zoledronic acid) injection package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007 Aug.
85. Miacalcin (calcitonin-salmon) package insert. East Hanover, NJ: Novartis; 2003.
86. Premarin (Conjugated Estrogens Tablets, USP) package insert. Philadelphia: Wyeth; 2005.

87. Evista (raloxifene) package insert. Indianapolis: Eli Lilly and Company; 2003.
88. Forteo (teriparatide [rDNA origin] injection) package insert. Indianapolis: Eli Lilly and Company; 2004.
89. McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med*. 2006; 354:821–31.
90. Greenspan SL, Bone HG, Marriott TB et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): results from the TOP study. *J Bone Miner Res*. 2005; 05-A-1321-ASBMR. Abstract.
91. Rubin CD, Pak CY, Adams-Huet B et al. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. *Arch Intern Med*. 2001; 161:2325–33.
92. Pak CY, Sakhaee K, Adams-Huet B et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. *Ann Intern Med*. 1995; 123:401–8.
93. Reginster JY, Meurmans L, Zegels B et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. *Ann Intern Med*. 1998; 129:1–8.
94. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *N Engl J Med*. 2004; 350:459–68.
95. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis Study (TROPOS). *J Clin Endocrinol Metab*. 2005; 90:2816–22.
96. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. *Ann Pharmacother*. 2005; 39:668–77.
97. Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. *Arthritis Rheum*. 2006; 54:1838–46.
98. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. *N Engl J Med*. 2002; 346:653–61.
99. Rizzoli R, Greenspan SL, Bone G III et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. *J Bone Miner Res*. 2002; 17:1988–96.
100. Brown JP, Kendler DL, McClung MR et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. *Calcif Tissue Int*. 2002; 71:103–11.
101. Miller PD, McClung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. *J Bone Miner Res*. 2005; 20:1315–22.
102. Tsun EC, Heck AM. Intermittent dosing of alendronate. *Ann Pharmacother*. 2001; 35:1471–5.
103. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. *Osteoporos Int*. 2004; 15:423–33.
104. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. *J Clin Endocrinol Metab*. 2005; 90:1294–301.
105. Ott SM. Long-term safety of bisphosphonates. *J Clin Endocrinol Metab*. 2005; 90:1897–9.
106. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. *Ann Intern Med*. 2006; 144:753–61.
107. Ensrud KE, Barrett-Connor EL, Schwartz A et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. *J Bone Miner Res*. 2004; 19:1259–69.
108. Ste-Marie LG, Sod E, Johnson T et al. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. *Calcif Tissue Int*. 2004; 75:469–76.
109. Pondel M. Calcitonin and calcitonin receptors: bone and beyond. *Int J Exp Pathol*. 2000; 81:405–22.
110. Zaidi M, Moonga BS, Abe E. Calcitonin and bone formation: a knockout full of surprises. *J Clin Invest*. 2002; 110:1769–71.
111. Lyritis GP, Paspatis I, Karachalios T et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. *Acta Orthop Scand Suppl*. 1997; 275:112–4.
112. Lyritis GP, Tsakalacos N, Magiasis B et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. *Calcif Tissue Int*. 1991; 49:369–72.
113. Naessen T, Persson I, Adami HO et al. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. *Ann Intern Med*. 1990; 113:95–103.
114. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. *JAMA*. 2001; 285:2891–7.
115. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. *BMC Musculoskelet Disord*. 2001; 2:7.
116. Weiss NS, Ure CL, Ballard JH et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. *N Engl J Med*. 1980; 303:1195–8.
117. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA*. 2003; 290:1729–38.
118. National Heart, Lung, and Blood Institute. Facts about postmenopausal hormone therapy. [www.nhlbi.nih.gov/health/women/pht\\_facts.htm](http://www.nhlbi.nih.gov/health/women/pht_facts.htm) (accessed 2005 May 6).
119. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med*. 1997; 337:1641–7.
120. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the

- NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA*. 2006; 295:2727–41.
121. Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med*. 2006; 355:125–37.
  122. Hodsman AB, Bauer DC, Dempster D et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. *Endocr Rev*. 2005; 26:688–703.
  123. DrugStore.com. Drug prices and information: Forteo. [www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00002897101&trx=1Z5066#info](http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00002897101&trx=1Z5066#info) (accessed 2007 Nov 29).
  124. Bone HG, Greenspan SL, McKeever C et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. *J Clin Endocrinol Metab*. 2000; 85:720–6.
  125. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. *JAMA*. 2003; 289:2525–33.
  126. Harris ST, Eriksen EF, Davidson M et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. *J Clin Endocrinol Metab*. 2001; 86:1890–7.
  127. Johnell O, Scheele WH, Lu Y et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab*. 2002; 87:985–92.
  128. Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *N Engl J Med*. 2003; 349:1207–15.
  129. Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. *N Engl J Med*. 2003; 349:1216–26.
  130. Black DM, Bilezikian JP, Ensrud KE et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med*. 2005; 353:555–65.
  131. Whyte MP. The long and the short of bone therapy. *N Engl J Med*. 2006; 354:860–3.
  132. European Medicines Agency. Preotact: European public assessment report. [www.emea.eu.int/humandocs/Humans/EPAR/preotact/preotact.htm](http://www.emea.eu.int/humandocs/Humans/EPAR/preotact/preotact.htm) (accessed 2007 Jul 26).
  133. NPS Pharmaceuticals, Inc. Preos: NPS updates status of Preos NDA. [www.drugs.com/nda/preos\\_060329.html](http://www.drugs.com/nda/preos_060329.html) (accessed 2006 Jul 27).
  134. Preotact (parathyroid hormone 1-84) package insert. Roskilde, Denmark: Nycomed Danmark ApS; 2006.
  135. Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. *Ann Intern Med*. 2007; 146:326–39.
  136. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. *Science*. 1983; 222:330–2.
  137. Kanis JA. Treatment of symptomatic osteoporosis with fluoride. *Am J Med*. 1993; 95:53S–61S.
  138. Riggs BL, Hodgson SF, O’Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. *N Engl J Med*. 1990; 322:802–9.
  139. Marie PJ. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. *Osteoporos Int*. 2003; 14(suppl 3):S9–12.
  140. Protelos (strontium ranelate) package insert. Neuilly sur Seine, France: Les Laboratoires Servier; 2004.
  141. Zimmerman SI, Girman CJ, Buie VC et al. The prevalence of osteoporosis in nursing home residents. *Osteoporos Int*. 1999; 9:151–7.
  142. Wallace RB. Bone health in nursing home residents. *JAMA*. 2000; 284:1018–9.
  143. Gaugris S, Heaney RP, Boonen S et al. Vitamin D inadequacy among post-menopausal women: a systematic review. *QJM*. 2005; 98:667–76.
  144. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. *Cochrane Database Syst Rev*. 2000; 4:CD001255.
  145. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. *BMJ*. 2006; 332:571–4.
  146. Gupta G, Aronow WS. Underuse of procedures for diagnosing osteoporosis and of therapies for osteoporosis in older nursing home residents. *J Am Med Dir Assoc*. 2003; 4:200–2.
  147. Schousboe JT, Ensrud KE, Nyman JA et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. *J Am Geriatr Soc*. 2005; 53:1697–1704.
  148. Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. *J Am Med Dir Assoc*. 2004; 5:98–100.
  149. Rojas-Fernandez C, Lapane KL, MacKnight C et al. Undertreatment of osteoporosis in residents of nursing homes: population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. *Endocr Pract*. 2002; 8:335–42.
  150. Colon-Emeric CS, Casebeer L, Saag K et al. Barriers to providing osteoporosis care in skilled nursing facilities: perceptions of medical directors and directors of nursing. *J Am Med Dir Assoc*. 2004; 5:361–6.
  151. Amin S, Felson DT. Osteoporosis in men. *Rheum Dis Clin North Am*. 2001; 27:19–47.
  152. National Osteoporosis Foundation. Osteoporosis: men. [www.nof.org/men/index.htm](http://www.nof.org/men/index.htm) (accessed 2005 Mar 23).
  153. Olszynski WP, Shawn Davison K, Adachi JD et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. *Clin Ther*. 2004; 26:15–28.
  154. Centers for Medicare and Medicaid Services. Bone mass measurement. [www.cms.hhs.gov/BoneMassMeasurement/](http://www.cms.hhs.gov/BoneMassMeasurement/) (accessed 2006 Jul 14).
  155. Biskobing DM. COPD and osteoporosis. *Chest*. 2002; 121:609–20.
  156. Shephard AJ, Cass AR, Carlson CA et al. Development and internal validation of the male osteoporosis risk estimation score. *Ann Fam Med*. 2007; 5:540–6.
  157. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. *N Engl J Med*. 2000; 343:604–10.

Approved by the ASHP Board of Directors on June 23, 2007.  
Developed through the ASHP Council on Therapeutics.

Eric J. MacLaughlin, Pharm.D., BCPS, and Cynthia L. Raehl, Pharm.D., FASHP, FCCP are gratefully acknowledged for drafting this therapeutic position statement.

Copyright © 2008, American Society of Health-System Pharmacists, Inc. All rights reserved.

The bibliographic citation for this document is as follows: American Society of Health-System Pharmacists. ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults. *Am J Health-Syst Pharm.* 2008; 65:343–57.